Concepedia
Statistics
Publications
11
Citations
479
H-Index
10
Active since
1996
Affiliations
Bayer (Switzerland)(Current)
Bayer (United States)
Rabin Medical Center
Novartis (Switzerland)
The Barbara Ann Karmanos Cancer Institute
Lucia Trandafir is an author at Bayer (Switzerland) specializing in oncology, pharmacology, and medicine.
Publications per year
1996–2021
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodón, Irene Braña, Lillian L. Siu et al. · Investigational New Drugs · 2014 · 189 citations
Medicine, Oncology, Pharmacology +9
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
P Soulié, Pierre Ruffiè, Lucia Trandafir et al. · Journal of Clinical Oncology · 1996 · 73 citations
Pharmacy, Oncology, Pharmacotherapy +15
Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients
Jacques Bonneterre, M. Spielman, Jean‐Paul Guastalla et al. · European Journal of Cancer · 1999 · 52 citations
Medicine, Oncology, Pharmacology +12
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
Alexander D. James, Lars Blumenstein, Ulrike Glaenzel et al. · Cancer Chemotherapy and Pharmacology · 2015 · 42 citations
Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +6
Higher doses of α-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma
Lucia Trandafir, Pierre Ruffiè, Christian Borel et al. · European Journal of Cancer · 1997 · 27 citations
1–5 of 11